Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.52 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.52 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7323325 | 1.00 | MME (0.56) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| Hydrochloric Acid SCHEMBL3905709 | 1.00 | MME (0.56) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| SCHEMBL38480 | 0.98 | MME (0.57) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| SCHEMBL161255 | 0.98 | MME (0.57) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| SCHEMBL7937827 | 0.98 | MME (0.57) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| SCHEMBL38479 | 0.98 | MME (0.57) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| SCHEMBL1324555 | 0.96 | MME (0.56) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| SCHEMBL1324550 | 0.96 | MME (0.56) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| Phosphine SCHEMBL28008446 | 0.96 | MME (0.56) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 | |
| Glycolic Acid SCHEMBL28512694 | 0.91 | NAALAD2 (0.53) | MMEL3MBTL1NPSR1CYP1A2NAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-221536707-U | Esterification device for producing L-phenylalanine methyl ester hydrochloride | 南京安伦化工科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| CN-116496178-B | Compound with syringic acid and amino acid structural fragments and synthesis and application thereof | 合肥工业大学 | 2024-10-29 | — | — | CN | disclosed |
| EP-3773563-B1 | PRODRUGS OF FUSED-BICYCLIC C5AR ANTAGONISTS | CHEMOCENTRYX INC (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-115634224-B | Application of TERPESTACIN derivative in preparation of medicine for treating brain glioma | 中国科学院南海海洋研究所 | 2024-10-01 | — | — | CN | disclosed |
| CN-113402436-B | Tertiary amino acid derivative, preparation method and application thereof | 安徽农业大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-115025814-B | Universal chiral catalyst and preparation method thereof | 中国科学院成都有机化学有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | PROTAGONIST THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| EP-1150975-A1 | 1-CARBOXYMETHYL-2-OXO-AZEPAN DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF MMP-12 | Aventis Pharmaceuticals Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000040577-A1 | 1-CARBOXYMETHYL-2-OXO-AZEPAN DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF MMP-12 | AVENTIS PHARMACEUTICALS INC. (US) | 2000-07-13 | — | — | WO | disclosed |
| US-5747503-A | INDENO(1,2B)PYROLES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0790250-A2 | Inhibitors of biogenic amine transporters | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-08-20 | — | — | EP | disclosed |
| US-5574060-A | INDANOPYRROLES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0713484-A1 | INHIBITORS OF BIOGENIC AMINE TRANSPORTERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-05-29 | — | — | EP | disclosed |
| WO-1995005364-A2 | INHIBITORS OF BIOGENIC AMINE TRANSPORTERS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-02-23 | — | — | WO | disclosed |
| EP-0259086-B1 | PRODRUGS OF ANTIHYPERCHOLESTEROLEMIC COMPOUNDS | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | disclosed |
| EP-0259086-A2 | Prodrugs of antihypercholesterolemic compounds | MERCK & CO. INC. (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4678806-A | INHIBITORS OF 3-HYDROXY-3-METHYLGLUTARYL COENZYME A REDUCTASE | MERCK & CO., INC. (US) | 1987-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295259-A1 | Conjugated Hepcidin Mimetics | HAMP, VIP, HDGF | SLC18A2 3500/4885SIGMAR1 2660/4885MME 612/4885 |
| US-20250170216-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | SLC18A2 2975/4885SIGMAR1 2042/4885MME 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.